Table 1.
Three Major Trials Comparing the Outcomes in Survival and Toxicity of Treatment in Pancreatic Cancer
| Trial 1 Accord10 | Trial 2 Impact11 | Trial 3 Erlotinib Phase III Trial32 | ||||
|---|---|---|---|---|---|---|
| Gemcitabine | FOLFIRNOX | Gemcitabine | Gemcitabine/Nab-Paclitaxel | Gemcitabine | Gemcitabine/Erlotinib | |
| Median overall survival (months) | 6.8 | 11.1 | 6.7 | 8.5 | 5.91 | 6.24 |
| Median progression-free survival (months) | 3.3 | 6.4 | 3.7 | 55 | 3.55 | 3.75 |
| General response rate | 9.4% | 31.6% | 7% | 23% | 8% | 8.6% |
| 1-year survival | 20.6% | 48.4% | 22% | 35% | 17% | 23% |
| Adverse effects | ||||||
| Neutropenia | 21% | 45.7% | 27% | 38% | – | – |
| Fatigue | 17.8% | 23.6% | 7% | 17% | 15% | 15% |
| Thrombocytopenia | 3.6% | 9.1% | 9% | 13% | – | – |
| Diarrhea | 1.8% | 12.7% | 1% | 6% | 2% | 6% |
| Infections | – | – | – | – | 17% | 16% |
| Other (febrile neutropenia, rush, stomatitis) | <24% | 17% | ||||